660 related articles for article (PubMed ID: 22249003)
1. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys.
Yamaoka M; Hara T; Hitaka T; Kaku T; Takeuchi T; Takahashi J; Asahi S; Miki H; Tasaka A; Kusaka M
J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):115-28. PubMed ID: 22249003
[TBL] [Abstract][Full Text] [Related]
2. Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats.
Hara T; Kouno J; Kaku T; Takeuchi T; Kusaka M; Tasaka A; Yamaoka M
J Steroid Biochem Mol Biol; 2013 Mar; 134():80-91. PubMed ID: 23146910
[TBL] [Abstract][Full Text] [Related]
3. Effect of an investigational CYP17A1 inhibitor, orteronel (TAK-700), on estrogen- and corticoid-synthesis pathways in hypophysectomized female rats and on the serum estradiol levels in female cynomolgus monkeys.
Yamaoka M; Hara T; Araki H; Kaku T; Hitaka T; Tasaka A; Kusaka M
J Steroid Biochem Mol Biol; 2013 Nov; 138():298-306. PubMed ID: 23856460
[TBL] [Abstract][Full Text] [Related]
4. The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.
Bird IM; Abbott DH
J Steroid Biochem Mol Biol; 2016 Oct; 163():136-46. PubMed ID: 27154414
[TBL] [Abstract][Full Text] [Related]
5. Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor.
Zhu H; Garcia JA
Curr Oncol Rep; 2013 Apr; 15(2):105-12. PubMed ID: 23371447
[TBL] [Abstract][Full Text] [Related]
6. Novel nonsteroidal inhibitor of cytochrome P450(17alpha) (17alpha-hydroxylase/C17-20 lyase), YM116, decreased prostatic weights by reducing serum concentrations of testosterone and adrenal androgens in rats.
Ideyama Y; Kudoh M; Tanimoto K; Susaki Y; Nanya T; Nakahara T; Ishikawa H; Yoden T; Okada M; Fujikura T; Akaza H; Shikama H
Prostate; 1998 Sep; 37(1):10-8. PubMed ID: 9721064
[TBL] [Abstract][Full Text] [Related]
7. Specificity of anti-prostate cancer CYP17A1 inhibitors on androgen biosynthesis.
Udhane SS; Dick B; Hu Q; Hartmann RW; Pandey AV
Biochem Biophys Res Commun; 2016 Sep; 477(4):1005-1010. PubMed ID: 27395338
[TBL] [Abstract][Full Text] [Related]
8. Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer.
Maity SN; Titus MA; Gyftaki R; Wu G; Lu JF; Ramachandran S; Li-Ning-Tapia EM; Logothetis CJ; Araujo JC; Efstathiou E
Sci Rep; 2016 Oct; 6():35354. PubMed ID: 27748439
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer.
Dreicer R; MacLean D; Suri A; Stadler WM; Shevrin D; Hart L; MacVicar GR; Hamid O; Hainsworth J; Gross ME; Shi Y; Webb IJ; Agus DB
Clin Cancer Res; 2014 Mar; 20(5):1335-44. PubMed ID: 24418642
[TBL] [Abstract][Full Text] [Related]
10. Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis.
Klus GT; Nakamura J; Li JS; Ling YZ; Son C; Kemppainen JA; Wilson EM; Brodie AM
Cancer Res; 1996 Nov; 56(21):4956-64. PubMed ID: 8895750
[TBL] [Abstract][Full Text] [Related]
11. Discovery and development of ODM-204: A Novel nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1.
Oksala R; Moilanen A; Riikonen R; Rummakko P; Karjalainen A; Passiniemi M; Wohlfahrt G; Taavitsainen P; Malmström C; Ramela M; Metsänkylä HM; Huhtaniemi R; Kallio PJ; Mustonen MV
J Steroid Biochem Mol Biol; 2019 Sep; 192():105115. PubMed ID: 29438723
[TBL] [Abstract][Full Text] [Related]
12. Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.
Petrylak DP; Gandhi JG; Clark WR; Heath E; Lin J; Oh WK; Agus DB; Carthon B; Moran S; Kong N; Suri A; Bargfrede M; Liu G
Invest New Drugs; 2015 Apr; 33(2):397-408. PubMed ID: 25556680
[TBL] [Abstract][Full Text] [Related]
13. Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.
Kaku T; Hitaka T; Ojida A; Matsunaga N; Adachi M; Tanaka T; Hara T; Yamaoka M; Kusaka M; Okuda T; Asahi S; Furuya S; Tasaka A
Bioorg Med Chem; 2011 Nov; 19(21):6383-99. PubMed ID: 21978946
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the potential of polyphenols as a CYP17 inhibitor free of adverse corticosteroid elevation.
Lin CJ; Cheng LC; Lin TC; Wang CJ; Li LA
Biochem Pharmacol; 2014 Aug; 90(3):288-96. PubMed ID: 24875446
[TBL] [Abstract][Full Text] [Related]
15. Orteronel for the treatment of prostate cancer.
Van Hook K; Huang T; Alumkal JJ
Future Oncol; 2014 Apr; 10(5):803-11. PubMed ID: 24799061
[TBL] [Abstract][Full Text] [Related]
16. P450-dependent enzymes as targets for prostate cancer therapy.
De Coster R; Wouters W; Bruynseels J
J Steroid Biochem Mol Biol; 1996 Jan; 56(1-6 Spec No):133-43. PubMed ID: 8603034
[TBL] [Abstract][Full Text] [Related]
17. Structural and Functional Evaluation of Clinically Relevant Inhibitors of Steroidogenic Cytochrome P450 17A1.
Petrunak EM; Rogers SA; Aubé J; Scott EE
Drug Metab Dispos; 2017 Jun; 45(6):635-645. PubMed ID: 28373265
[TBL] [Abstract][Full Text] [Related]
18. Preclinical assessment of Orteronel(®), a CYP17A1 enzyme inhibitor in rats.
Zainuddin M; Vinod AB; Gurav SD; Police A; Kumar A; Mithra C; Dewang P; Kethiri RR; Mullangi R
Eur J Drug Metab Pharmacokinet; 2016 Feb; 41(1):1-7. PubMed ID: 25297456
[TBL] [Abstract][Full Text] [Related]
19. YM116, 2-(1H-imidazol-4-ylmethyl)-9H-carbazole, decreases adrenal androgen synthesis by inhibiting C17-20 lyase activity in NCI-H295 human adrenocortical carcinoma cells.
Ideyama Y; Kudoh M; Tanimoto K; Susaki Y; Nanya T; Nakahara T; Ishikawa H; Fujikura T; Akaza H; Shikama H
Jpn J Pharmacol; 1999 Feb; 79(2):213-20. PubMed ID: 10202857
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.
Cai C; Chen S; Ng P; Bubley GJ; Nelson PS; Mostaghel EA; Marck B; Matsumoto AM; Simon NI; Wang H; Chen S; Balk SP
Cancer Res; 2011 Oct; 71(20):6503-13. PubMed ID: 21868758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]